Terms: = Endocrine gland cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
594 results:
1. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
2. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
3. Combined inhibition of her2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
4. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
5. Thyroid Ultrasound Image Database and Marker Mask Inpainting Method for Research and Development.
Li X; Fu C; Xu S; Sham CW
Ultrasound Med Biol; 2024 Apr; 50(4):509-519. PubMed ID: 38267314
[TBL] [Abstract] [Full Text] [Related]
6. PARP Inhibitors in Breast cancer: a Short Communication.
Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
[TBL] [Abstract] [Full Text] [Related]
7. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
8. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian cancer SKOV3-TR Cells.
Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
[TBL] [Abstract] [Full Text] [Related]
9. Antibody-Drug Conjugates in Gynecologic cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract] [Full Text] [Related]
10. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
11. Prioritization of Fluorescence In Situ Hybridization (FISH) Probes for Differentiating Primary Sites of neuroendocrine Tumors with Machine Learning.
Pietan L; Vaughn H; Howe JR; Bellizzi AM; Smith BJ; Darbro B; Braun T; Casavant T
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139230
[TBL] [Abstract] [Full Text] [Related]
12. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of Ovarian cancer.
Chen T; Wang Y; Zhu L; Wu J; Lin J; Huang W; Yan D
ACS Appl Mater Interfaces; 2023 Dec; 15(50):58067-58078. PubMed ID: 38056905
[TBL] [Abstract] [Full Text] [Related]
13. Bilateral co-secretory lesions presenting with coexisting Cushing syndrome and primary aldosteronism: a case report.
Gao H; Li L; Chen F; Ren Y; Chen T; Tian H
BMC Endocr Disord; 2023 Nov; 23(1):263. PubMed ID: 38017509
[TBL] [Abstract] [Full Text] [Related]
14. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
15. The role of sialylation in gynecologic cancers.
Yang ST; Liu CH; Chao WT; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):651-654. PubMed ID: 37678990
[TBL] [Abstract] [Full Text] [Related]
16. Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with her2-Negative Metastatic Breast cancer and Recurrent Ovarian cancer.
Landry CA; Blanter J; Ru M; Fasano J; Klein P; Shao T; Bhardwaj A; Tiersten A
Oncology; 2024; 102(1):9-16. PubMed ID: 37598677
[TBL] [Abstract] [Full Text] [Related]
17. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
[TBL] [Abstract] [Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract] [Full Text] [Related]
19. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
20. Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates.
Xu K; Han J; Yang L; Cao L; Li S; Hong Z
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446189
[TBL] [Abstract] [Full Text] [Related]
[Next]
